Phaseline

Companies › Dianthus Therapeutics

Dianthus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Claseprubart
complement C5 inhibitor
FCER2, COMPPhase 3Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor NeuropathyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06537999ClaseprubartPhase 2Multifocal Motor NeuropathyNeurologyDec 2026
NCT06282159ClaseprubartPhase 2Myasthenia Gravis, GeneralizedNeurologyOct 2028
NCT07647510ClaseprubartPhase 3Myasthenia Gravis, GeneralizedNeurologyDec 2028
NCT06858579ClaseprubartPhase 3Chronic Inflammatory Demyelinating PolyneuropathyNeurologyDec 2028

Specialist investors

Held by 17 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FCER2 (1) COMP (1)

Companies with the same targets

AstraZeneca

Companies built like this

Tiziana Life Sciences Abcuro Keros Therapeutics Acumen Pharmaceuticals Vor Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.